MedTrace Logo

Safety and Pharmacokinetic Study of BIO 300 Capsules

NCT00504335 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-03-17

No results posted yet for this study

Summary

This trial is designed to evaluate the safety and pharmacokinetics of BIO 300 capsules when administered orally to healthy male and female volunteers. BIO 300 is expected to be safe for use starting at 500 mg.

Conditions

  • Acute Radiation Syndrome

Interventions

DRUG

BIO 300 Capsules

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Humanetics Corporation

    lead INDUSTRY

Principal Investigators

  • John L Zenk, MD · Humanetics Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2007-09-30
Completion
2007-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504335 on ClinicalTrials.gov